Calculation of the cost-effectiveness
 of subcutaneous administration of trastuzumab

Abstract

Rational selection of medicines with an assessment of their pharmacoeconomic effectiveness is the most effective way to
 ensure safe and efficient treatment and economical use of budget funds allocated for drug therapy, as well as to reduce the
 time of hospitalization and treatment of patients.
 The purpose of the research was to evaluate the pharmacoeconomic effectiveness of using the subcutaneous and intravenous forms of drug Trastuzumab.
 Research tasks:
 1. Estimate costs when using subcutaneous trastuzumab in an outpatient chemotherapy room (OCR).
 2. Estimate costs when using intravenous trastuzumab in a day patient department (DPD).
 3. Estimate costs when using intravenous trastuzumab in a round-the-clock hospital.
 Results: The paper presents the pharmacoeconomic analysis of targeted therapy with trastuzumab in two forms for intravenous administration (IV) and trastuzumab emtansine for subcutaneous administration (SC) in breast cancer by cost minimization method.
 The costs of used drugs are according to the price-list of the unified national distributor SK Pharmacia as of January 1, 2018.
 At comparable efficacy and toxicity, the estimated cost-effectiveness of trastuzumab per 100 patients per year is
 KZT 16,939,600 ($ 50,972) for SC administration in OCR and IV administration in DPD vs. KZT 41,783,200 ($ 125,728) for
 SC administration in OCR and IV administration in a round-the-clock hospital.
 Conclusions: Based on the above, the subcutaneous form is economically feasible for conducting targeted therapy with
 trastuzumab.